Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2023.10.084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Analyses of the De-Escalation of Dual Antiplatelet Therapy in Treatment of Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention in Taiwan.
Acta Cardiol Sin
January 2025
Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University.
Background: Dual antiplatelet therapy (DAPT) is the standard treatment for acute myocardial infarction (MI). This study aimed to investigate the use of DAPT and de-escalation after discharge in real-world practice among patients with acute MI undergoing percutaneous coronary intervention (PCI) in Taiwan.
Methods: Using the Taiwan National Health Insurance Research Database, we included patients who received PCI for acute MI and survived to discharge with DAPT from 2011 to 2021.
Comparison of the Effects of Indobufen and Aspirin in Older Patients with Coronary Artery Disease After Coronary Drug-Eluting Stent Implantation: A Prospective Randomized Single-Center Study.
Clin Appl Thromb Hemost
December 2024
Department of Cardiology, the Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
After coronary drug-eluting stent (DES) implantation, dual antiplatelet therapy (DAPT, usually aspirin in combination with a P2Y12 inhibitor) is necessary. However, older patients are prone to aspirin intolerance or resistance. Indobufen has been reported as an ideal alternative to aspirin.
View Article and Find Full Text PDFRandomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics.
Clin Transl Sci
November 2024
Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Article Synopsis
- Antiplatelet therapy, particularly with P2Y receptor inhibitors alongside aspirin, is essential for treating coronary artery disease, and different medication options can help tailor patient care.
- A study investigated the effects of a specific genetic mutation (G143E in CES1) on the effectiveness of clopidogrel and ticagrelor in inhibiting platelet aggregation in patients.
- Results showed that the G143E mutation significantly affected platelet response to clopidogrel, but not to ticagrelor, indicating ticagrelor may provide more consistent treatment for patients with clopidogrel response-altering genetics.
Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review.
Thromb J
October 2024
Department of Cardiology, West China Hospital of Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Article Synopsis
- Ticagrelor is a new and effective P2Y12 inhibitor used in managing patients with STEMI, showing advantages over the traditional drug clopidogrel in preventing blood clots after treatment.
- *Key clinical trials, including TREAT and MIRTOS, demonstrate ticagrelor's superior ability to inhibit platelets without significantly increasing bleeding risks, suggesting it's a promising option.
- *Despite its potential benefits, clopidogrel is still the recommended treatment, so more research is needed to better understand ticagrelor's long-term impacts and best usage in cardiovascular care.*
Background: Patients with atrial fibrillation and severe chronic kidney disease have higher risks of bleeding, thromboembolism, and mortality. However, optimal anticoagulant choice in these high-risk patients remains unclear.
Methods And Results: Using deidentified electronic health records from the Optum Labs Data Warehouse, adults with atrial fibrillation and severe chronic kidney disease (estimated glomerular filtration rate <30 mL/min per 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!